Welcome Panthers Fans!

Check Out The All NEW & Original Carolina Panthers Den Message Board! - Many New Improvements & Features For Everyone! - New Photo Gallery Added!.... Please Register To Participate On The Forums Today! .... Updated 2007 Panthers Schedule Posted In Our Forums! .... Join Us For All The LATEST News & Discussions On Your Carolina Panthers Everyday!: Keyshawn Johnson Cut by Panthers!-Discuss on our Message Board NOW! .... Download Our NEW Panthers Den Toolbar And Get Panthers News Sent To Your Desktop! ..... Plenty Of Fun & Games: Enter Our Arcade Tournaments And Compete Against Other Forum Members! ....Try Our New Sports Bookie & Casino And Rack Up Your 'Gold Points!' .....Login To See Who Our Newest Member Of The Month Is And Find Out How YOU Can Be Our Next WINNER!!! .... We Have Something For Everyone! - Don't Miss Out On All The "Crazy Feline Fun!" At Carolina Panthers Den! - The Most "Interactive" Panthers Fansite & Message Board On The Net!!! - GUARANTEED!!!


Additionally it is quite enjoyable when you carry out and function exercises with other folks.

Cellular Study has designed the Precise assays for high-throughput applications where accuracy and precision are desired, and which are currently badly served by qPCR. With the launch of our following early access system for the Precise Single Cell Assay, we want to help researchers go further and quantify transcripts from an individual cell even. We welcome new customers interested in participating in the program, stated Steve Fodor, Ph.D., Chief Executive Officer of Cellular Research. THE COMPLETE assays combine sample and molecular indexing in 96 and 384 sample types, enabling clients to sequence up to 4,608 samples within a sequencing run without the need for additional purchase in new equipment or extensive training.As well as the lack of exclusivity for Seroquel IR, generic competition also decreased revenues for Nexium, Merrem and Atacand in Western Europe. Income in Established ROW was down 12 %, mainly due to a thirty % decline in Canada because of generic competition for Crestor and Atacand. Revenue in Emerging Marketplaces was up 1 %, reflecting lack of exclusivity for Seroquel IR and Crestor in Brazil and difficult market circumstances in Mexico. Revenue development was also influenced by the source chain issues; adjusted because of this impact, Emerging Marketplace revenues could have increased by about 8 %. Simon Lowth, Interim CEO, commenting on the full total results, said: Once we expected, the increased loss of exclusivity on some essential brands and tough marketplace conditions have led to a decline in income and income in the next quarter.